AGENT FOR ENHANCING CORNEAL EPITHELIAL BARRIER FUNCTION

摘要

FIELD: medicine.;SUBSTANCE: group of inventions refers to ophthalmology. The group of inventions refers to pharmacological action of a compound functioning as a PPARr agonist on the corneal epithelial barrier function. The PPARr agonist, such as rivoglitazone, DRF-2593, GW-544 and BMS-298585, perfectly enhances the corneal epithelial barrier function in the study of enhancing the corneal epithelial barrier function, and therefore it is useful as a preventive agent or therapeutic agent for an ocular infection or eye complaints of unknown aetiology caused by the decreased corneal epithelial barrier function.;EFFECT: group of inventions provides enhancing the corneal epithelial barrier function in the patients with diabetes, age-related decrease in the corneal epithelial barrier function, and patients underwent refractive surgery, such as PRK (photorefractive keratectomy) and LASIK (laser keratomileusis in situ), and cataract surgery.;12 cl, 2 tbl, 4 ex